Carregant...

Gemtuzumab Ozogamicin for Treatment of Acute Myeloid Leukemia

INTRODUCTION: Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin. Despite the known clinical efficacy in relapsed/refractory acute myeloid leukemia (AML), GO was withdrawn from the market in 20...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Expert Rev Clin Pharmacol
Autors principals: Baron, Jeffrey, Wang, Eunice S.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6661897/
https://ncbi.nlm.nih.gov/pubmed/29787320
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/17512433.2018.1478725
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!